$JAZZ
Jazz Pharmaceuticals PLC

2020 Q2 Form 10-Q Financial Statement

#000123252420000054 Filed on August 04, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $562.4M $534.1M
YoY Change 5.3% 6.72%
Cost Of Revenue $28.00M $27.70M
YoY Change 1.08% -20.17%
Gross Profit $530.2M $495.7M
YoY Change 6.95% 7.45%
Gross Profit Margin 94.27% 92.81%
Selling, General & Admin $191.4M $176.0M
YoY Change 8.74% 10.99%
% of Gross Profit 36.1% 35.5%
Research & Development $78.92M $62.38M
YoY Change 26.51% 11.14%
% of Gross Profit 14.89% 12.58%
Depreciation & Amortization $67.80M $65.00M
YoY Change 4.31% 10.54%
% of Gross Profit 12.79% 13.11%
Operating Expenses $270.3M $238.4M
YoY Change 13.39% -31.35%
Operating Profit $198.1M $204.3M
YoY Change -3.01% 33.34%
Interest Expense -$26.21M -$18.23M
YoY Change 43.74% -7.19%
% of Operating Profit -13.23% -8.93%
Other Income/Expense, Net
YoY Change
Pretax Income $171.5M $184.1M
YoY Change -6.88% 42.25%
Income Tax $54.80M -$78.70M
% Of Pretax Income 31.96% -42.74%
Net Earnings $114.8M $261.9M
YoY Change -56.17% 183.68%
Net Earnings / Revenue 20.41% 49.03%
Basic Earnings Per Share $2.07 $4.62
Diluted Earnings Per Share $2.06 $4.56
COMMON SHARES
Basic Shares Outstanding 55.41M shares 56.71M shares
Diluted Shares Outstanding 55.86M shares 57.43M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.696B $882.7M
YoY Change 92.15% 8.29%
Cash & Equivalents $786.1M $637.7M
Short-Term Investments $1.226B $621.5M
Other Short-Term Assets $112.7M $75.37M
YoY Change 49.54% 35.47%
Inventory $92.53M $69.00M
Prepaid Expenses $49.11M $31.71M
Receivables $351.9M $311.2M
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.302B $1.370B
YoY Change 68.05% 4.83%
LONG-TERM ASSETS
Property, Plant & Equipment $128.3M $127.2M
YoY Change 0.85% -32.38%
Goodwill $918.0M $925.0M
YoY Change -0.75% -1.23%
Intangibles $2.286B $2.688B
YoY Change -14.95% -5.43%
Long-Term Investments
YoY Change
Other Assets $48.83M $40.84M
YoY Change 19.57% 74.48%
Total Long-Term Assets $3.764B $4.119B
YoY Change -8.61% 1.89%
TOTAL ASSETS
Total Short-Term Assets $2.302B $1.370B
Total Long-Term Assets $3.764B $4.119B
Total Assets $6.067B $5.489B
YoY Change 10.53% 2.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $50.04M $82.22M
YoY Change -39.14% 162.03%
Accrued Expenses $266.9M $218.8M
YoY Change 22.02% -15.47%
Deferred Revenue $3.633M $4.720M
YoY Change -23.03%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $33.39M $33.39M
YoY Change 0.0% 0.0%
Total Short-Term Liabilities $410.0M $369.5M
YoY Change 10.95% 6.19%
LONG-TERM LIABILITIES
Long-Term Debt $2.070B $1.568B
YoY Change 32.01% 0.61%
Other Long-Term Liabilities $134.8M $120.7M
YoY Change 11.7% -41.32%
Total Long-Term Liabilities $2.205B $1.689B
YoY Change 30.56% -4.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $410.0M $369.5M
Total Long-Term Liabilities $2.205B $1.689B
Total Liabilities $2.614B $2.058B
YoY Change 27.04% -2.55%
SHAREHOLDERS EQUITY
Retained Earnings $878.2M $1.022B
YoY Change -14.06% 2.15%
Common Stock $2.499B $2.171B
YoY Change 15.09% 6.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.142B $2.983B
YoY Change
Total Liabilities & Shareholders Equity $6.067B $5.489B
YoY Change 10.53% 2.61%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income $114.8M $261.9M
YoY Change -56.17% 183.68%
Depreciation, Depletion And Amortization $67.80M $65.00M
YoY Change 4.31% 10.54%
Cash From Operating Activities $182.5M $148.8M
YoY Change 22.65% -22.46%
INVESTING ACTIVITIES
Capital Expenditures -$105.7M -$41.70M
YoY Change 153.48% -63.83%
Acquisitions
YoY Change
Other Investing Activities -$635.5M $39.00M
YoY Change -1729.49% -151.72%
Cash From Investing Activities -$741.1M -$2.700M
YoY Change 27348.15% -98.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 642.6M -56.20M
YoY Change -1243.42% -294.46%
NET CHANGE
Cash From Operating Activities 182.5M 148.8M
Cash From Investing Activities -741.1M -2.700M
Cash From Financing Activities 642.6M -56.20M
Net Change In Cash 84.00M 89.90M
YoY Change -6.56% 197.68%
FREE CASH FLOW
Cash From Operating Activities $182.5M $148.8M
Capital Expenditures -$105.7M -$41.70M
Free Cash Flow $288.2M $190.5M
YoY Change 51.29% -37.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
-689000 USD
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Entity Central Index Key
EntityCentralIndexKey
0001232524
dei Entity Registrant Name
EntityRegistrantName
Jazz Pharmaceuticals plc
jazz Discrete Income Tax Expense Benefit Resulting From Intra Entity Intellectual Property Asset Transfer
DiscreteIncomeTaxExpenseBenefitResultingFromIntraEntityIntellectualPropertyAssetTransfer
112300000 USD
CY2020Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2019Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
-440000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
85000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
-449000 USD
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33500
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L2
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1032470
dei Entity Address Address Line1
EntityAddressAddressLine1
Fifth Floor, Waterloo Exchange,
dei Entity Address Address Line2
EntityAddressAddressLine2
Waterloo Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Dublin 4
dei Entity Address Country
EntityAddressCountry
IE
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
D04 E5W7
dei Country Region
CountryRegion
353
dei City Area Code
CityAreaCode
1
dei Local Phone Number
LocalPhoneNumber
634-7800
dei Security12b Title
Security12bTitle
Ordinary shares, nominal value $0.0001 per share
dei Trading Symbol
TradingSymbol
JAZZ
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55458631 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
786082000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
637344000 USD
CY2020Q2 us-gaap Investments
Investments
910000000 USD
CY2019Q4 us-gaap Investments
Investments
440000000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
351920000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
355987000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
92534000 USD
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
33387000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
50043000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
45732000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
78608000 USD
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
49109000 USD
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
39434000 USD
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
112701000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
78895000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
2302346000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1630268000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
128259000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
131506000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
133179000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
139385000 USD
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2286126000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2440977000 USD
CY2020Q2 us-gaap Goodwill
Goodwill
918021000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
920018000 USD
CY2020Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
243395000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
221403000 USD
CY2020Q2 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
6347000 USD
CY2019Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
7426000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
48828000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
47914000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6066501000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5538897000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
562436000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
266918000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
269686000 USD
CY2020Q2 us-gaap Assets
Assets
6066501000 USD
CY2019Q4 us-gaap Assets
Assets
5538897000 USD
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
33387000 USD
CY2020Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
55979000 USD
CY2019Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
10965000 USD
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3633000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4720000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
409960000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
364490000 USD
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3588000 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4861000 USD
CY2020Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2069669000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1573870000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
144264000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
151226000 USD
CY2020Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
162376000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
224095000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
134839000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
109374000 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
6000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
6000 USD
CY2020Q2 jazz Nonvoting Euro Deferred Shares
NonvotingEuroDeferredShares
55000 USD
CY2019Q4 jazz Nonvoting Euro Deferred Shares
NonvotingEuroDeferredShares
55000 USD
CY2020Q2 jazz Capital Redemption Reserve
CapitalRedemptionReserve
472000 USD
CY2019Q4 jazz Capital Redemption Reserve
CapitalRedemptionReserve
472000 USD
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2499135000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2266026000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-236109000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-223393000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
878246000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1067815000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
3141805000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3110981000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
534133000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1097162000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1042319000 USD
CY2020Q2 jazz Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment
CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment
28008000 USD
CY2019Q2 jazz Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment
CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment
27676000 USD
jazz Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment
CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment
56665000 USD
jazz Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment
CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment
61182000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
191406000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
399806000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
176014000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
343961000 USD
CY2020Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
78922000 USD
CY2019Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
62384000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
165029000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
122489000 USD
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
62974000 USD
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
61576000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
125821000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
118461000 USD
CY2020Q2 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
3000000 USD
CY2019Q2 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
2200000 USD
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
205250000 USD
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
58200000 USD
CY2020Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2019Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
136139000 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
364310000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
329850000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1088710000 USD
us-gaap Costs And Expenses
CostsAndExpenses
704293000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
198126000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
204283000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
8452000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
338026000 USD
CY2020Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-26210000 USD
CY2019Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-18234000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-44706000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-36156000 USD
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-464000 USD
CY2019Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1933000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1596000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2544000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
171452000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
184116000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-37850000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
299326000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54754000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-78650000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3467000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-49534000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1715000 USD
CY2020Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1897000 USD
CY2019Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-868000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1761000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
114801000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
261898000 USD
us-gaap Net Income Loss
NetIncomeLoss
-43032000 USD
us-gaap Net Income Loss
NetIncomeLoss
347099000 USD
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.07
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.09
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.06
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.01
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55413000 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56707000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55684000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56955000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55864000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57427000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55684000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57753000 shares
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
114801000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
261898000 USD
us-gaap Net Income Loss
NetIncomeLoss
-43032000 USD
us-gaap Net Income Loss
NetIncomeLoss
347099000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
20730000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
13319000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-9260000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-7823000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
597000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-3081000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-3456000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-4822000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
21327000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
10238000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-12716000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-12645000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
136128000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
272136000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55748000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
334454000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3110981000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13264000 USD
CY2020Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
13547000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28731000 USD
CY2020Q1 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
139053000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-34043000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-157833000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
2808500000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
176260000 USD
CY2020Q2 jazz Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature Repurchase
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeatureRepurchase
12069000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4440000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6547000 USD
CY2020Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1116000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30599000 USD
CY2020Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
7484000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
21327000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
114801000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
3141805000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
2757422000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3057000 USD
CY2019Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
13810000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27861000 USD
CY2019Q1 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
111249000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-22883000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
85201000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
2730447000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7033000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6032000 USD
CY2019Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1003000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28658000 USD
CY2019Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
59869000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
10238000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
261898000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
2983434000 USD
us-gaap Net Income Loss
NetIncomeLoss
-43032000 USD
us-gaap Net Income Loss
NetIncomeLoss
347099000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
125821000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
118461000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
59258000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
55841000 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
136139000 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
us-gaap Depreciation
Depreciation
9266000 USD
us-gaap Depreciation
Depreciation
6894000 USD
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
205250000 USD
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
58200000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-82768000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-151347000 USD
jazz Provision For Losses On Accounts Receivable And Inventory
ProvisionForLossesOnAccountsReceivableAndInventory
4078000 USD
jazz Provision For Losses On Accounts Receivable And Inventory
ProvisionForLossesOnAccountsReceivableAndInventory
2403000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-4475000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
24793000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
22584000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3496000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
779000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3640000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
47574000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
18826000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
18562000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
44853000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15929000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1982000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1067000 USD
jazz Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-6422000 USD
jazz Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-7399000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5264000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-14096000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6972000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-59031000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
45481000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
29050000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2360000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3054000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
25912000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
14177000 USD
jazz Increase Decrease In Operating Lease Liabilities Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent
-6978000 USD
jazz Increase Decrease In Operating Lease Liabilities Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent
431000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
455488000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
351100000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
565000000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
630000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7520000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21911000 USD
jazz Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination
PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination
205250000 USD
jazz Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination
PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination
58200000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
113000000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
25500000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
1040475000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
360975000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-801245000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
163414000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
981381000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
500000000 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
24251000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
16122000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
14663000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
14813000 USD
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
16693000 USD
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
16693000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
146537000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
171118000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
332888000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
500000000 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
494851000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-186502000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-356000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
148738000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
328117000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
637344000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
309622000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
786082000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
637739000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risk</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had foreign exchange forward contracts with notional amounts totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$283.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the outstanding foreign exchange forward contracts had a net liability fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had interest rate swap contracts with notional amounts totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$300.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. These outstanding interest rate swap contracts had a net liability fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">. The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, allowances on receivables were not material. As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> customers accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>87%</span></span><span style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, Express Scripts Specialty Distribution Services, Inc. and its affiliates, or ESSDS, which accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>73%</span></span><span style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, and McKesson Corporation and affiliates, or McKesson, which accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>14%</span></span><span style="font-family:inherit;font-size:10pt;"> of gross accounts receivable. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> customers accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>89%</span></span><span style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, ESSDS, which accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>77%</span></span><span style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, and McKesson, which accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>12%</span></span><span style="font-family:inherit;font-size:10pt;"> of gross accounts receivable. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to Xyrem, the API is manufactured for us by a single source supplier and the finished product is manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based Xyrem supplier.</span></div>
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1696082000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1696082000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
786082000 USD
CY2020Q2 us-gaap Investments
Investments
910000000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1077344000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1077344000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
637344000 USD
CY2019Q4 us-gaap Investments
Investments
440000000 USD
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3100000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
7600000 USD
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000000.0 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
9800000 USD
CY2020Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
4500000 USD
CY2020Q2 us-gaap Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement
DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
1454000 USD
CY2020Q2 us-gaap Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement
DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
7244000 USD
CY2019Q4 us-gaap Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement
DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
2508000 USD
CY2019Q4 us-gaap Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement
DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
1697000 USD
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
15856000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
13595000 USD
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
42582000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
36658000 USD
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
34096000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
28355000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
92534000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
78608000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
920018000 USD
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-1997000 USD
CY2020Q2 us-gaap Goodwill
Goodwill
918021000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3290445000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1004319000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2286126000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3292501000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
990850000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2301651000 USD
CY2020Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
3290445000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1004319000 USD
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2286126000 USD
CY2019Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
3431827000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
990850000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2440977000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
130647000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
215415000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
170572000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
170572000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
170572000 USD
CY2020Q2 jazz Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
1428348000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2286126000 USD
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
186528000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
186763000 USD
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
58269000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
55257000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
128259000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
131506000 USD
CY2020Q2 jazz Accrued Rebates And Other Sales Deductions
AccruedRebatesAndOtherSalesDeductions
122204000 USD
CY2019Q4 jazz Accrued Rebates And Other Sales Deductions
AccruedRebatesAndOtherSalesDeductions
96860000 USD
CY2020Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
51289000 USD
CY2019Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
80531000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12763000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12728000 USD
CY2020Q2 jazz Accrued Inventory Related Liabilities
AccruedInventoryRelatedLiabilities
12364000 USD
CY2019Q4 jazz Accrued Inventory Related Liabilities
AccruedInventoryRelatedLiabilities
7816000 USD
CY2020Q2 jazz Sales Return Reserve
SalesReturnReserve
8030000 USD
CY2019Q4 jazz Sales Return Reserve
SalesReturnReserve
3462000 USD
CY2020Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
7064000 USD
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1037000 USD
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6221000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7665000 USD
CY2020Q2 jazz Accrued Interest
AccruedInterest
6110000 USD
CY2019Q4 jazz Accrued Interest
AccruedInterest
7540000 USD
CY2020Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
6031000 USD
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
6931000 USD
CY2020Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
3420000 USD
CY2019Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
10946000 USD
CY2020Q2 jazz Accrued Collaboration Costs Current
AccruedCollaborationCostsCurrent
3161000 USD
CY2019Q4 jazz Accrued Collaboration Costs Current
AccruedCollaborationCostsCurrent
2494000 USD
CY2020Q2 jazz Accrued Clinical Trial Liability
AccruedClinicalTrialLiability
2965000 USD
CY2019Q4 jazz Accrued Clinical Trial Liability
AccruedClinicalTrialLiability
3141000 USD
CY2020Q2 jazz Accrued Construction In Progress
AccruedConstructionInProgress
442000 USD
CY2019Q4 jazz Accrued Construction In Progress
AccruedConstructionInProgress
3015000 USD
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
24854000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
25520000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
266918000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
269686000 USD
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
2103056000 USD
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
33387000 USD
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
1607257000 USD
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
33387000 USD
CY2020Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2069669000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1573870000 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
16693000 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
275499000 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
33387000 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
517494000 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
575000000 USD
CY2020Q2 jazz Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
1000000000 USD
CY2020Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
2418073000 USD
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
5410000 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
6056000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
10700000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
11926000 USD
CY2020Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
890000 USD
CY2019Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
619000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
1760000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
1220000 USD
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
0 USD
CY2019Q2 us-gaap Variable Lease Cost
VariableLeaseCost
1000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
1000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
4000 USD
CY2020Q2 us-gaap Sublease Income
SubleaseIncome
67000 USD
CY2019Q2 us-gaap Sublease Income
SubleaseIncome
158000 USD
us-gaap Sublease Income
SubleaseIncome
224000 USD
us-gaap Sublease Income
SubleaseIncome
320000 USD
CY2020Q2 us-gaap Lease Cost
LeaseCost
6233000 USD
CY2019Q2 us-gaap Lease Cost
LeaseCost
6518000 USD
us-gaap Lease Cost
LeaseCost
12237000 USD
us-gaap Lease Cost
LeaseCost
12830000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
133179000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
139385000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12763000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12728000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
144264000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
151226000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
157027000 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
163954000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y3M18D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y8M12D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.053
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.053
us-gaap Operating Lease Payments
OperatingLeasePayments
11404000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
8240000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
533000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
152142000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
10078000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
21203000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
21219000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
21489000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
23786000 USD
CY2020Q2 jazz Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
104655000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
202430000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
45403000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
157027000 USD
CY2020Q2 us-gaap Unrecorded Unconditional Purchase Obligation Due In Next Rolling Twelve Months
UnrecordedUnconditionalPurchaseObligationDueInNextRollingTwelveMonths
71700000 USD
us-gaap Oci Before Reclassifications Net Of Tax Attributable To Parent
OciBeforeReclassificationsNetOfTaxAttributableToParent
-13784000 USD
us-gaap Reclassification From Aoci Current Period Net Of Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
-1068000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-12716000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
114801000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
261898000 USD
us-gaap Net Income Loss
NetIncomeLoss
-43032000 USD
us-gaap Net Income Loss
NetIncomeLoss
347099000 USD
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55413000 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56707000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55684000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56955000 shares
CY2020Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
451000 shares
CY2019Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
720000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
798000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55864000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57427000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55684000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57753000 shares
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.07
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.09
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.06
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.01
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
562436000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
534133000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1097162000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1042319000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
562436000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
534133000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1097162000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1042319000 USD
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
9581000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2360000 USD
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
7221000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30604000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28289000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
59258000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
55841000 USD
CY2020Q2 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
2924000 USD
CY2019Q2 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
4473000 USD
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
6670000 USD
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
8140000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
27680000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
23816000 USD
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
52588000 USD
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
47701000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54800000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3500000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-78700000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-49500000 USD
CY2020Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.319
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.092
CY2019Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.427
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.165
CY2019Q2 jazz Discrete Income Tax Expense Benefit Resulting From Intra Entity Intellectual Property Asset Transfer
DiscreteIncomeTaxExpenseBenefitResultingFromIntraEntityIntellectualPropertyAssetTransfer
112300000 USD

Files In Submission

Name View Source Status
0001232524-20-000054-index-headers.html Edgar Link pending
0001232524-20-000054-index.html Edgar Link pending
0001232524-20-000054.txt Edgar Link pending
0001232524-20-000054-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
jazz-20200630.xsd Edgar Link pending
jazz-20200630_cal.xml Edgar Link unprocessable
jazz-20200630_def.xml Edgar Link unprocessable
jazz-20200630_lab.xml Edgar Link unprocessable
jazz-20200630_pre.xml Edgar Link unprocessable
jazz2020q2doc.htm Edgar Link pending
jazz2020q2doc_htm.xml Edgar Link completed
jazzq22020ex101.htm Edgar Link pending
jazzq22020ex102.htm Edgar Link pending
jazzq22020ex103.htm Edgar Link pending
jazzq22020ex311.htm Edgar Link pending
jazzq22020ex312.htm Edgar Link pending
jazzq22020ex321.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending